Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2021.05.058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thermochromic Hydrogel Smart Window for Iron-Chromium Flow Batteries: Dual Band Modulation and Efficient Energy Storage.
Chemistry
September 2025
State Key Laboratory of Heavy Oil Processing, China University of Petroleum (Beijing), Beijing, 102249, China.
This study introduces the HydroTherm-Flow Smart Window (HTF Window), the first groundbreaking integration of thermochromic windows and Fe-Cr redox flow batteries (Fe-Cr RFBs), achieving dual functionalities of dynamic solar modulation-via dual-band (visible + near-infrared, NIR) modulation-and high-efficiency energy storage in a single component. Leveraging tunable hydroxypropyl cellulose (HPC) hydrogels, it enables ultrafast optical switching and autonomous nighttime opacity, overcoming the slow response and privacy limitations of conventional thermochromic systems. By repurposing the window as a compact electrolyte reservoir, it reduces the RFB spatial footprint while enhancing ionic conductivity by 30% via hydrogel "ion highways," achieving 77% energy efficiency with a 40% reduction in the solar heat gain coefficient.
View Article and Find Full Text PDFBleomycin Electrosclerotherapy (BEST) of Slow-Flow Vascular Malformations (SFVMs) in Children.
J Pediatr Surg
September 2025
Interdisziplinäres Zentrum für Gefäßanomalien (IZGA), LMU University Hospital, LMU Munich, München, Germany; Department of Radiology, LMU University Hospital, LMU Munich, München, Germany.
Rationale And Objectives: Bleomycin electrosclerotherapy (BEST) is a promising treatment for slow-flow vascular malformations (SFVMs). Due to limited paediatric data, this study aimed to assess the safety, effectiveness, and patient-reported outcomes of BEST in children with SFVMs.
Material And Methods: This monocenter cohort study included patients <18 years with symptomatic SFVMs treated by BEST.
Assessment of thoracoamniotic shunt catheter patency using pulsed-wave Doppler and color flow mapping: A case report.
J Obstet Gynaecol Res
September 2025
Fetal-Maternal Medicine, Obstetrics, Gifu Prefectural General Medical Center, Gifu, Gifu, Japan.
Thoracoamniotic shunting is an effective treatment for fetal pleural effusion. Catheter obstruction is a serious and frequently occurring phenomenon that often requires re-shunting; however, accurate diagnosis remains challenging. We present a case in which pulsed-wave Doppler and color flow mapping were used to evaluate fluid flow through a thoracoamniotic shunt catheter.
View Article and Find Full Text PDFBeyond Membranes: Recent Advances in Membrane-Free Fuel Cells.
Chem Rec
September 2025
Instituto Universitario de Materiales y Nanotecnología, Departamento de Química, Universidad de La Laguna (ULL), PO Box 456, La Laguna, 38200, Santa Cruz de Tenerife, España.
As energy demand increases and the need for sustainable solutions grows, fuel cells have emerged as a promising solution, capable of converting chemical energy into electricity in a clean and combustion-free process. This technology not only improves energy efficiency but also leads to significant emission reductions, paving the way for a cleaner future. Among the various fuel cell technologies, proton-exchange membrane fuel cells (PEMFCs) have been at the forefront (Abdelkareem et al.
View Article and Find Full Text PDFSafety and Clinical Outcome of Bleomycin-Electrosclerotherapy (BEST) Treating Lymphatic Malformations (LMs).
Cardiovasc Intervent Radiol
September 2025
Department of Radiology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 83177, Munich, Germany.
Introduction: Bleomycin-electrosclerotherapy (BEST) is a novel treatment for slow-flow vascular malformations (SFVMs), most studied in venous malformations. This study specifically evaluated its safety and clinical outcome in lymphatic/lymphatic-dominant lympho-venous malformations (LMs/ld-LVMs).
Materials And Methods: A monocentric cohort with symptomatic LMs or ld-LVMs treated by BEST was retrospectively assessed.